Heterozygous mutations in the gene encoding the CHD (chromodomain helicase DNA-binding domain) member CHD7, an ATPdependent chromatin remodeller homologous to the Drosophila trithorax-group protein Kismet 1,2 , result in a complex constellation of congenital anomalies called CHARGE syndrome, which is a sporadic, autosomal dominant disorder characterized by malformations of the craniofacial structures, peripheral nervous system, ears, eyes and heart 3, 4 . Although it was postulated 25 years ago that CHARGE syndrome results from the abnormal development of the neural crest, this hypothesis remained untested 5 . Here we show that, in both humans and Xenopus, CHD7 is essential for the formation of multipotent migratory neural crest (NC), a transient cell population that is ectodermal in origin but undergoes a major transcriptional reprogramming event to acquire a remarkably broad differentiation potential and ability to migrate throughout the body, giving rise to craniofacial bones and cartilages, the peripheral nervous system, pigmentation and cardiac structures 6, 7 . We demonstrate that CHD7 is essential for activation of the NC transcriptional circuitry, including Sox9, Twist and Slug. In Xenopus embryos, knockdown of Chd7 or overexpression of its catalytically inactive form recapitulates all major features of CHARGE syndrome. In human NC cells CHD7 associates with PBAF (polybromo-and BRG1-associated factorcontaining complex) 8 and both remodellers occupy a NC-specific distal SOX9 enhancer 9 and a conserved genomic element located upstream of the TWIST1 gene. Consistently, during embryogenesis CHD7 and PBAF cooperate to promote NC gene expression and cell migration. Our work identifies an evolutionarily conserved role for CHD7 in orchestrating NC gene expression programs, provides insights into the synergistic control of distal elements by chromatin remodellers, illuminates the pathoembryology of CHARGE syndrome, and suggests a broader function for CHD7 in the regulation of cell motility.
Heterozygous mutations in the gene encoding the CHD (chromodomain helicase DNA-binding domain) member CHD7, an ATPdependent chromatin remodeller homologous to the Drosophila trithorax-group protein Kismet 1,2 , result in a complex constellation of congenital anomalies called CHARGE syndrome, which is a sporadic, autosomal dominant disorder characterized by malformations of the craniofacial structures, peripheral nervous system, ears, eyes and heart 3, 4 . Although it was postulated 25 years ago that CHARGE syndrome results from the abnormal development of the neural crest, this hypothesis remained untested 5 . Here we show that, in both humans and Xenopus, CHD7 is essential for the formation of multipotent migratory neural crest (NC), a transient cell population that is ectodermal in origin but undergoes a major transcriptional reprogramming event to acquire a remarkably broad differentiation potential and ability to migrate throughout the body, giving rise to craniofacial bones and cartilages, the peripheral nervous system, pigmentation and cardiac structures 6, 7 . We demonstrate that CHD7 is essential for activation of the NC transcriptional circuitry, including Sox9, Twist and Slug. In Xenopus embryos, knockdown of Chd7 or overexpression of its catalytically inactive form recapitulates all major features of CHARGE syndrome. In human NC cells CHD7 associates with PBAF (polybromo-and BRG1-associated factorcontaining complex) 8 and both remodellers occupy a NC-specific distal SOX9 enhancer 9 and a conserved genomic element located upstream of the TWIST1 gene. Consistently, during embryogenesis CHD7 and PBAF cooperate to promote NC gene expression and cell migration. Our work identifies an evolutionarily conserved role for CHD7 in orchestrating NC gene expression programs, provides insights into the synergistic control of distal elements by chromatin remodellers, illuminates the pathoembryology of CHARGE syndrome, and suggests a broader function for CHD7 in the regulation of cell motility.
To investigate the role of CHD7 in human NC formation, we used human embryonic stem cells (hESCs) to establish an in vitro model of NC migration and differentiation. In brief, hESCs were induced to form neuroectodermal spheres or 'rosettes' 10 , which spontaneously attached and gave rise to stellate-morphology migratory cells (Fig. 1a) . We show that these migratory cells grow preferentially on fibronectin (Supplementary Fig. 1 ), that they are distinct from neural rosettes (Supplementary Fig. 2 ), that they express early NC genes (Fig. 1b) , that they migrate to the craniofacial mesenchyme and heart on transplantation to the chick embryo neural tube ( Supplementary Fig. 3 ), and that they are multipotent and differentiate spontaneously into peripheral neurons, glia, melanocytes and mesenchymal cell types ( Supplementary Fig. 4 ). The observed gene expression, adhesion, migration and differentiation characteristics are consistent with an early NC cell identity; we therefore termed these cells human neural crest-like cells (hNCLCs).
Human NCLCs express high levels of CHD7 messenger RNA ( Supplementary Fig. 5a ). To address CHD7 function during hNCLC formation, hESCs were infected with a lentivirus encoding doxycycline-inducible CHD7 short hairpin RNA (shRNA), resulting in a doxycycline-dependent downregulation of CHD7 mRNA and protein levels ( Supplementary Fig. 5b-d) . The formation and morphology of neural rosettes were not appreciably affected by CHD7 knockdown ( Supplementary Fig. 6a, b) , although CHD7 shRNAexpressing rosettes attached less efficiently (compare the top and bottom panels in Fig. 1c ). The formation of migratory hNCLCs was markedly affected by CHD7 downregulation ( Fig. 1c ; quantified in Supplementary Fig. 6c ).
Next we tested the effects of CHD7 shRNA expression (as assayed by the linked expression of red fluorescent protein (RFP)) on the relative abundance of cells positive for PAX3 and TWIST1. PAX3/RFP doublepositive cells were equally represented in CHD7 and control shRNAinfected neuroectodermal cells (Fig. 1d) . In contrast, TWIST1/RFP double-positive cells were significantly underrepresented in CHD7 compared with control shRNA-infected hNCLCs derived from the same neuroectodermal population (Fig. 1d) . Moreover, TWIST1/ RFP double-positive cells infected with CHD7 shRNA had markedly lower RFP levels than controls. Similar results were obtained with an independent CHD7 shRNA ( Supplementary Fig. 7 ). Our results indicate that CHD7 is crucial for the formation of migratory hNCLCs in vitro.
To investigate whether CHD7 is essential for NC migration in vivo, we used a Xenopus laevis embryo model. CHD7 is highly conserved between humans and Xenopus ( Supplementary Fig. 8a ). During Xenopus embryogenesis, Chd7 is expressed in the NC and in neural and preplacodal ectodermal tissues (Fig. 2a) . Injection of a morpholino oligonucleotide (MO) targeting translation of both non-allelic X. laevis Chd7 transcripts efficiently depleted Chd7 levels in embryos ( Supplementary Fig. 8b, c) . To assay the migration of cephalic NC cells to pharyngeal arches we established an in vivo migration assay described in detail in Supplementary Fig. 9a . Injection of Chd7, but not of control MO, perturbed cell migration to pharyngeal arches; this defect was partly rescued by the concomitant injection of human CHD7 mRNA. Moreover, overexpression of human CHD7 mRNA containing the substitution of a conserved lysine residue in its ATPase domain (CHD7 ATPase disruption targeted to the dorsal-anterior region, Chd7 MO and/or CHD7 mRNA were injected together along with a lineage tracer into a single dorsal-animal blastomere of eight-cell-stage embryos. Injection of Chd7 MO resulted in a nearly fully penetrant absence of pharyngeal arch labelling in tailbud-stage embryos; CHD7 mRNA alone had no effect, and simultaneous injection of Chd7 MO and CHD7 mRNA resulted in a partial rescue of pharyngeal arch labelling (Supplementary Fig. 9c ).
Phenotypic analyses of hCHD7 ATPase K998R mRNA-injected tadpoles revealed defects consistent with the major CHARGE syndrome features: missing or malformed otolith, a part of the vestibular system analogous to the human ear; coloboma of the eye with or without microphthalmia; malformations of the craniofacial cartilage; and heart defects, including abnormal positioning of the truncus arteriosus and cardiac outflow tract ( Supplementary Fig. 10 ). Moreover, observed facial width compression and decreased eye distance are suggestive of mild midline defects ( Supplementary Fig. 11) ; arhinencephaly is often associated with CHARGE 4 . Similar defects were observed on injection of Chd7 MO, although we noted a strong dosage-sensitive response, with high doses leading to neurula-stage lethality ( Supplementary Fig. 12 ). In sum, Chd7 is required for NC migration in vivo, and impairment of its function recapitulates major CHARGE features in Xenopus embryos.
The effect of Chd7 downregulation on NC migration may result from interference with the regulatory circuitry affecting one or multiple steps in NC formation. To dissect molecular processes controlled by Chd7, we examined the expression of transcription factors critical for the following: establishing the competence of the neural-plate border territory to induce NC (Pax3, Zic1 and Msx1); NC survival (MycII); and formation of the multipotent, migratory NC (Sox9, Twist and Slug) 6 . Expression of Pax3, Zic1, Msx1 and MycII was not appreciably affected by Chd7 knockdown, which is consistent with unperturbed induction and survival of the border territory cells (Fig. 2c) . In contrast, expression of multipotent, migratory NC specifiers Twist, Slug (Snail2) and Sox9 was severely diminished on Chd7 knockdown (Fig. 2c) . Defects in Sox9 and Twist expression were fully or partly rescued by concomitant injection of CHD7 mRNA, indicating specificity (Fig. 2d ). These observations demonstrate that Chd7 controls gene expression programs for NC migration and specification but is not essential for the earliest inductive events at the border territory.
Observed eye coloboma and otolith defects suggest that, in addition to NC, Chd7 is also required for the development of placodal derivatives. In agreement, Chd7 is expressed in ectodermal placodes during embryogenesis (Fig. 2a) . Moreover, otic placode-specific expression of Sox9, as well as optic and otic placode-specific expression of Pax2 (mutations in which result in ocular colobomas and hearing loss in humans 11 ) is affected by Chd7 knockdown ( Fig. 2c and Supplementary Fig. 13 ).
To identify molecular partners of CHD7 in the NC, we immunopurified CHD7 from hNCLCs by using an antibody that depleted endogenous protein from extracts to near completion (Supplementary Fig. 14) . Because there was limited availability of hNCLCs, we performed parallel purifications from differentiated human teratocarcinoma NT2 cells. Identification of associated proteins by mass spectrometry revealed multiple subunits of BAF/PBAF, PBAFspecific polypeptides, and poly(ADP-ribose) polymerase 1 (PARP1) , AP2-a, nestin, SOX9 and HNK1, as indicated; nuclei were stained with 4,6-diamidino-2-phenylindole. Lower panels, single-channel images; upper panels, merged images. More than 95% of hNCLCs expressed SOX9, p75 and AP2-a, whereas about 30% expressed HNK1, which is consistent with HNK1 marking a subset of the early NC 21, 22 . c, Formation of hNCLCs is affected by CHD7 knockdown. CHD7 or control shRNA-expressing attached neural rosettes were identified by RFP expression at 32.5 magnification (left panels) and 310 magnification (right panels); images contain merged fluorescence and bright field. Yellow arrows highlight RFPexpressing, migrating hNCLCs. Scarce cells migrating from the CHD7 shRNA-expressing rosettes emitted greatly decreased levels of red fluorescence (white arrow). Scale bars, 250 mm. Dox, doxycycline. in CHD7, but not in control immunoprecipitates from both cell types ( Supplementary Fig. 15 ). PBAF and BAF are related chromatinremodelling complexes of the SWI/SNF family, which share multiple components including the catalytic subunit BRG1 but are distinguished by the presence of unique subunits, such as PBAF-specific PB1, ARID2 and BRD7 (refs 12-14; Fig. 3a ). Immunoblot analyses of CHD7 immunoprecipitates and reciprocal immunoprecipitations with anti-BAF170 and anti-PB1 antibodies confirmed the specificity of the CHD7-PBAF association (Fig. 3b, c) .
Brg1-containing complexes have broad roles in early development 15 . To target PBAF function specifically in dorsal-anterior structures, Brg1 or Brd7 MO was injected into a single dorsal-animal blastomere of eight-cell-stage embryos (Fig. 3e) . Similarly to what we observed for Chd7, Brg1 or Brd7 knockdown did not affect expression of neural-plate border specifiers but resulted in the downregulation of Twist and Slug (Fig. 3d) 9a ). Tailbud-stage embryos were assayed for NC cell migration to pharyngeal arches, evident as three migratory tracts (see diagram at left). Cell migration to pharyngeal arches is highlighted with filled arrows, whereas defects in pharyngeal arch migration are depicted with open arrows. Bright-field and fluorescence images of whole embryos are shown in Supplementary Fig. 9b . c, Effect of Chd7 knockdown on NC transcriptional circuitry. Two-cell-stage embryos were injected with Chd7 MO into a single blastomere, resulting in Chd7 depletion in half of the embryo (see diagram). Neurula-stage embryos were analysed by RNA in situ hybridization with the indicated probes. Sox9 was detected in two major expression domains: the neural crest (blue arrow) and prospective otic placode (red arrow). Figs 8c and 17) . Next we investigated Chd7 and PBAF co-occupancy at genomic targets. Chd7 binding to the ENCODE regions 16 and genome-wide Brg1 occupancy 17 were reported for mouse ESCs. We identified Brg1 sites within ENCODE regions and investigated the overlap with Chd7 sites: 81% of Brg1 regions were bound by Chd7, whereas 34% of Chd7 sites were occupied by Brg1 (Fig. 3e) . For comparison, none of the 126 Suz12 sites present within ENCODE regions were bound by Chd7 (not shown). Furthermore, 89% of regions occupied by both Chd7 and Brg1 were located more than 1 kilobase (kb) from the nearest transcription start site (TSS) (Fig. 3f) . Chd7-Brg1-bound regions were preferentially enriched for histone H3 monomethylated at lysine 4 (H3K4me1), a mark previously associated with enhancers 18 , in contrast with the trimethylated H3K4me3, a mark associated with TSS 19 . Binding footprints at these regions showed stronger and broader signals than footprints at sites bound only by Chd7 (Supplementary Fig. 18) .
We speculated that, during human NC formation, CHD7 and BRG1 together occupy distal regulatory elements controlling the expression of critical NC specifiers. A conserved enhancer located 251 kb upstream of the human SOX9 gene (NC E ) mediates expression in the cranial NC and otic placodes 9 . Although regulatory elements controlling NC-specific expression of TWIST1 are unknown, we identified an evolutionarily conserved genomic region located 2.4 kb upstream of the TWIST1 TSS. Chromatin immunoprecipitation (ChIP) analyses from hNCLCs showed enrichment of H3K4me1, CHD7 and BRG1 at both SOX9 NC E and TWIST1 upstream element, in comparison with the respective TSS or with another enhancer, mediating SOX9 expression in the notochord, gut and pancreas (Fig. 4a, b) enriched at SOX9 and TWIST1 distal elements in hESCs or unattached neural rosettes (hNPCs), demonstrating a NC-specific regulation of these genomic regions ( Supplementary Fig. 19 ).
To address whether CHD7 and PBAF synergistically control NC gene expression and migration in vivo we took advantage of the dosage-sensitive effect of Chd7 and Brd7 MOs. Injection of Chd7 or Brd7 MO at 3.3 mM resulted in diminished Twist expression, but halving the concentration of each MO to 1.7 mM had only a minor effect (Fig. 4c) . However, simultaneous injection of both MOs at 1.7 mM led to a marked downregulation of Twist (Fig. 4c) . Similarly, Chd7 or Brd7 MO at 1.7 mM had only a minor effect on cell migration to pharyngeal arches, whereas simultaneous injection of both MOs at the same concentration resulted in the absence of pharyngeal arch labelling (Fig. 4d) . Taken together, our results suggest that during NC formation CHD7 and PBAF synergistically regulate activity of distal genomic elements that control the expression of critical NC transcription factors, in turn allowing for transcriptional reprogramming, acquisition of multipotency and migratory potential (Fig. 4e) .
METHODS SUMMARY
hNCLC derivation. WA-09 (H9; WiCell) cells were passaged as described 20 . For neuroepithelial induction, H9 cells were harvested by digestion with 1 mg ml 21 collagenase IV. Feeder-free and Matrigel-depleted hESC clusters were transferred to neural induction medium; at 6-9 days of differentiation, neural rosettes spontaneously attached and hNCLCs migrated out. Rosettes were manually dissected away and the resultant P0 hNCLCs were passaged with accutase and replated on dishes coated with 1 mg ml 21 fibronectin. Quantification of hNCLC formation defect. Lentivirus-infected hESC populations selected as described in Methods were differentiated to neuroepithelium in the presence or absence of 1 mg ml 21 doxycycline. Attached spheres with migrating cells were imaged on day 9. For quantification, the percentage of attached RFP-expressing spheres that gave rise to migratory hNCLCs was determined. In vivo migration assay. Two-cell-stage Xenopus embryos were injected into both blastomeres with 450 pg of kaede mRNA and into a single blastomere with 3.3 mM Chd7 or control MO, and/or 9 ng of wild-type or ATPase K998R CHD7 mRNA. At the neurula stage (stage 17) a subset of anterior tissues was irradiated with ultraviolet under a Leica DM4500 microscope with a rectangular pinhole. Tailbud-stage (stage 25) embryos were imaged, and asymmetry in pharyngeal arch migration was quantified.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Neural induction medium. The neural induction medium consisted of a 1:1 ratio of DMEM-F12 and neurobasal media (Invitrogen) supplemented with 0.5 3 N2 (Invitrogen), 0.5 3 B27 (Invitrogen), 5 mg ml 21 insulin (Sigma), 20 ng ml 21 basic fibroblast growth factor (Peprotech), 20 ng ml 21 epidermal growth factor (Sigma) and 1 3 penicillin-streptomycin. hNCLC differentiation. P0 and P1 NCLCs were plated on coverslips coated with 100 mg ml 21 ornithine and 5 mg ml 21 laminin in growth-factor-reduced medium (3:1 ratio of DMEM-F12 and neurobasal media supplemented with 0.25 3 B27, 0.5 3 glutamine and 1 3 antibiotic-antimycotic mix). The medium was changed weekly. Cells were fixed and analysed after 1, 4 or 7 weeks of differentiation. Differentiation of mature mesenchymal progenitors into specific lineages (adipocytes and osteoblasts) after 3-4 weeks of amplification was performed essentially as described 23 . Immunocytochemistry. Cells were fixed in 4% paraformaldehyde. For stainings with antibodies recognizing intracellular epitopes, phosphate-buffered saline (PBS) containing 0.5 mg ml 21 BSA and 0.1% Triton X-100 was used for blocking and permeabilization. For cell surface stainings, Triton X-100 was eliminated from the blocking buffer. Primary antibodies and dilutions used for stainings are listed in Supplementary Table 2 . Appropriate secondary antibodies labelled with Alexa 488, Rhodamine or Alexa 594, and/or counterstaining with 4,6-diamidino-2-phenylindole, was used for visualization with a confocal (Leica TSC SP2) or inverted (Leica DMI 6000B) microscope. RNA isolation and RT-qPCR. For RT-qPCR, total RNA was extracted with TRIzol followed by treatment with turbo DNase I (Ambion) and reverse transcription (Superscript II; Invitrogen). RT-qPCR analyses were performed with a Roche Lightcycler 480 in accordance with the manufacturer's recommendations. Primer sequences are listed in Supplementary Table 3 . In ovo transplantation. Neural rosettes with migrating cells were labelled with 5 mM 5-chloromethylfluorescein diacetate (CMFDA, a green fluorescent viable dye) (Molecular Probes) for 1 h. Cells were washed with medium and cultured for 12 h. Fertile white leghorn chicken eggs (Charles River) were incubated at 37 uC in a humidified incubator. For transplantation, the vitelline membrane of H&H stage 8/9 embryos was peeled off and a small fragment of the dorsal neural tube was dissected out with a tungsten needle and replaced either with NCLCs that migrated out of the rosettes or with a part of the rosette. Embryos 6 h after transplantation in which the transplanted cells were still associated with the neural tube and had not been dispersed as a result of mechanical agitation were incubated further and imaged in ovo at 32 h after transplantation. Lentiviral infection and selection. pSM2c retroviral constructs encoding miRNA-resembling shRNAs targeting human CHD7 (RHS4529-NM_017780) or control, verified non-silencing shRNA (RHS4335) were purchased from Open Biosystems. A MluI-XhoI fragment from pSM2c encoding the appropriate hairpin was re-cloned into a doxycycline-inducible lentiviral vector, TRIPZ (no. RHS4696-99634943; Open Biosystems) 24, 25 . VSVG pseudotyped lentiviruses were produced in 293T cells as described previously 26 . Undifferentiated hESCs were infected in suspension for 2 h with a concentrated virus. Infected hESCs were amplified for 1 week, replated on puromycin-resistant mouse embryonic fibroblasts and then selected with 2 mg ml 21 puromycin for 10 days before differentiation. Protein extraction, immunoprecipitation and immunoblotting. For largescale amplification, hESCs were passaged as 2-20-cell clusters with accutase, as described previously 27 . Nuclei were prepared from hESCs and NT2 derivatives with the Dignam protocol 28 and extracted with buffer containing 100 mM Tris/ HCl pH 8.0, 300 mM NaCl, 0.1% Nonidet P40, 10% glycerol, 1 mM EDTA, 1 mM EGTA and 1 mM dithiothreitol (DTT) and freshly added 1 mM phenylmethylsulphonyl fluoride (PMSF) and protease inhibitor cocktail (Roche). For immunoprecipitations, 0.5-2 mg of nuclear extracts with the salt concentration adjusted to 250 mM NaCl were incubated at 4 uC with specific antibodies and Protein A-Dynal beads for 2 h. Beads were washed and bound proteins were eluted in 0.5 M NH 4 OH, 0.5 mM EDTA. The eluates were analysed by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) as described below, or by immunoblotting with antibodies listed in Supplementary Table 2 .
For Xenopus extracts, about 30 staged embryos were washed twice in 0.1 3 Marks modified Ringers solution followed by a wash in Dignam buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 1 mM DTT, 1 mM PMSF and protease inhibitors (Roche)). Embryos were homogenized in a Dounce homogenizer with a loose pestle in 500 ml of Dignam buffer A containing 2 M sucrose. The homogenate was layered on top of 3.5 ml of Dignam buffer A containing 2.05 M sucrose in a 5-ml ultracentrifuge tube, and centrifuged at 46,000 r.p.m. for 1 h in a Beckman SW50.1 rotor. The pelleted nuclei were boiled in Laemmli buffer before protein separation by SDS-PAGE 29 .
HPLC/MS/MS analysis. HPLC/MS/MS analysis was performed in an integrated system that included an Agilent 1100 series nanoflow liquid chromatography system and an LTQ two-dimensional ion trap mass spectrometer equipped with a nanoelectrospray ionization source. The eluate from each immunoprecipitation, with either a polyclonal anti-CHD7 antibody (ab31824) or a control rabbit IgG, was freeze-dried and then reconstituted in 30-50 ml of 50 mM ammonium biocarbonate; the pH was adjusted to 7-9. Digestion with trypsin (200 ng of enzyme) lasted 2 h at 37 uC. The resulting peptides were cleaned with C 18 ZipTips (Millipore Corp.) in accordance with the manufacturer's instructions. Subsequently, tryptic peptides were separated in a capillary HPLC column (11 cm length 3 75 mm inner diameter) packed in house with Luna C 18 resin (5 mm particle size, 10 nm pore diameter) (Phenomenex). Peptides were eluted from the column with a gradient of 2.0-90% buffer B (90% acetonitrile, 9.95% water, 0.05% acetic acid) in a 2 h LC/MS/MS analysis. LC/MS/MS was operated in a data-dependent mode such that the ten strongest ions in each MS scan were subjected to collisionally activated dissociation with a normalized collisionally activated dissociation energy of 35%. A database search was conducted with Mascot 2.1 and the NCBInr database. One missed cleavage was allowed for database search. The protein score is derived from the ions' scores. More details can be found at http://www.matrixscience.com/help/interpretation_help.html. Antibody production. To generate antibodies recognizing Xenopus Chd7 two rabbits were immunized (Covance) with a recombinant, purified immunogen corresponding to the amino-terminal region of Xenopus Chd7 amplified with the primers 59-ATGGCAGACCCTGGCATGATGAGTTTATTT-39 (forward) and 59-GTAATTTCCCATCTGTTGAACATGCTGAGG -39 (reverse). Chromatin immunoprecipitation (ChIP) and ChIP-qPCR. ChIP analyses from undifferentiated hESC, hNPC and hNCLC cell populations were performed as described 30 . For each ChIP, 100-500 mg of chromatin was used. ChIP-qPCR signals were standardized to input chromatin (percentage of input). Primer sequences used for amplification are shown in Supplementary Table 3 . Genomic data analyses. Chd7 (ref. 16) or Brg1 (ref. 17) binding regions in mouse ESCs were as defined in the corresponding publications. For calculating the overlaps between Chd7 and Brg1, we first determined Brg1-bound regions occurring within mouse ENCODE regions (n 5 131). Subsequently, Chd7 regions were extended 500 base pairs on each side. At least one base pair of overlap between the Chd7-extended and Brg1 regions was required to consider a region as co-occupied by both proteins (Brg1 regions were not extended because they were already quite large, with a median size of 6 kb). Chd7-Brg1 co-occupied regions were mapped with respect to protein-coding gene TSS, according to Refseq gene annotations based on the Mm7 mouse genome. For binding footprints, mouse ESC Chd7 binding signal was obtained from Gene Expression Omnibus (GEO) data set GSE14460 (ref. 16 ) and analysed with Genomic Signal Aggregator (GSA) (http://zlab.bu.edu/GSA/; ref. 31) , considering a window size of 63,000 base pairs. Morpholino oligonucleotide design, CHD7 mRNA cloning and mutagenesis. Translation-blocking morpholinos targeting Xenopus laevis Chd7 (Chd7 MO, 59-AACTCATCATGCCAGGGTCTGCCAT-39), Brd7 (Brd7 MO, 59-GCTTC TTATGTTTTTTCCCCATTGC-39) and Brg1 (Brg1 MO, 59-TCACTGCTAAC CTGTCCCCGAATCC-39) 32 were obtained from Gene Tools LLC (http:// www.gene-tools.com). The human CHD7 complementary DNA fragment (KIAA1416) from human brain cDNA library was obtained from the Kazusa DNA Research Institute. The missing 59 and 39 fragments were PCR-amplified from the human teratocarcinoma NT2 cell line with the primers 59 (primer 1, 59-cgcgtggcgcgccttatggcagatccaggaatgatgagtc-39; primer 2, 59-agtcgactctgtccagg ttcggaattccctt-39) and 39 (primer 1, 59-cgcgttcgatgtttgaccgccttctcact-39; primer 2, 59-agtcgaccgtacgctggaactggtactggttattcatcattttcattg-39). Amplified fragments were ligated to KIAA1416 by means of internal MfeI and NotI sites for the 59 and 39 fragments, respectively. The resulting full-length human CHD7 transcript was cloned into pcDNA vector (Invitrogen) as a Flag-His-CHD7 fusion transcript. 59-capped and poly(A)-tailed mRNAs were transcribed from AvrIIlinearized template by using SP6 RNA polymerase. Catalytically inactive ATPase mutant CHD7 protein (CHD7 K998R ) was generated with the use of a modified PCR-based site-directed mutagenesis strategy 33 . Two primer sets (set 1: forward primer, 59-gcaccaagggaattgactg-39; reverse primer, 59-tcccaaacccatttcatctgcta aaatg-39; set 2: forward primer, 59-atccagtccattacatttctctatgag-39; reverse primer, 59-gtgtgggttcgacgtaggag-39) containing the desired point mutation were used to PCR-amplify two fragments of CHD7 from the pcDNA vector containing wildtype human CHD7. The ligated product was cloned into the pcDNA-CHD7 vector, replacing the corresponding region of wild-type CHD7. Xenopus embryology. Xenopus laevis embryos were staged in accordance with standard procedures 34 . To knock down Chd7 expression levels, Chd7 MO was injected into both blastomeres of two-cell-stage embryos at final concentrations of 1.7, 3.3, 4 and 5 mM in a 5 or 10 nl volume. Embryo viability was scored throughout development to the tadpole stage (stage 35). For injections into dorsal-animal blastomere, a 1.25 nl volume was injected into a single dorsalanimal blastomere at the eight-cell stage. For phenotypic trait analysis at the
